Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 22, 2004 Brian Gorman	Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving.
The Motley Fool October 27, 2005 Brian Gorman	Bausch & Lomb's Cloudy Quarter An accounting scandal at a Brazilian subsidiary clouded third-quarter results, but the underlying business still looks good. Investors, take note.
The Motley Fool April 11, 2006 Rick Aristotle Munarriz	Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news.
The Motley Fool June 7, 2006 Stephen D. Simpson	Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse.
The Motley Fool August 7, 2006 Stephen D. Simpson	Advanced Medical Optics Still a Little Bloodshot This eye-care stock has done relatively well despite some ongoing sales issues.
The Motley Fool October 20, 2005 Stephen D. Simpson	Wide Eyes at Alcon Excellent margin performance fueled exceptional growth for this eye-care titan. This is a strong and valuable cash-producing franchise, and it deserves a premium valuation -- but how much of a premium?
The Motley Fool May 31, 2007 Billy Fisher	Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note.
The Motley Fool November 2, 2005 Stephen D. Simpson	AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note.
The Motley Fool September 10, 2007 Lawrence A. Rothman	Cooper Needs a Clearer Vision Earnings reports from vision-correction specialist Cooper show that revenue did rise, but gross margins decreased, and management lowered guidance significantly.
The Motley Fool February 9, 2006 Stephen D. Simpson	Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough.
The Motley Fool July 5, 2005 Brian Gorman	Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note.
The Motley Fool May 1, 2006 Stephen D. Simpson	Alcon Still Not Living Up to Valuation Though this is a very solid medical technology company, its valuation still looks too high.
The Motley Fool December 15, 2003 Carla Pasternak	Cooper Eyes Big Gains The stock of rapidly growing contact lens maker Cooper is worth a look.
The Motley Fool June 7, 2007 Billy Fisher	Envisioning a Clear Future at Cooper The contact lens and eye care-product company posts a second-quarter loss upon restructuring, but revenues continue to grow. The outlook is fairly positive for Cooper shareholders for the remainder of the year.
The Motley Fool December 13, 2005 Stephen D. Simpson	Take a Good, Long Look at Cooper Tough competition is eating away at the contact lens maker's growth. This is a stock that could require an above-average level of patience and tolerance for risk in the meantime.
The Motley Fool August 17, 2005 David Meier	The Power of Margins The way you think about margins can give you an investing edge.
The Motley Fool September 13, 2006 Tim Beyers	Why Margins Matter What are margins? Investors, there are three that matter when studying an income statement. Let's run though each, one at a time.
Chemistry World July 30, 2013 Emma Stoye	Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb.
The Motley Fool August 31, 2006	Foolish Fundamentals: Margins Margins are important, but how you use margin information is more important to your investing success. Don't stay on the surface when analyzing margins. Your portfolio will thank you for it later.
The Motley Fool July 25, 2006 Stephen D. Simpson	An Eye-Opening Quarter at Alcon Good news may have been overdue from the eye-care company, but the jubilation seems overdone. Investors, take note.
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool August 10, 2010 Seth Jayson	Marginal Performance at Alcon The more Alcon keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.
The Motley Fool March 7, 2007 Steven Mallas	1-800 CONTACTS: I Just Don't See It This lens maker is still one investors should avoid.
The Motley Fool March 5, 2007 Rich Smith	Foolish Forecast: Focus on 1-800 Contacts The contact lens purveyor reports fourth-quarter and full-year 2006 earnings shortly. Investors, here is what you can expect to see.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
The Motley Fool May 17, 2007 Matt Koppenheffer	Bausch & Lomb: How Much Is Too Much? Private equity's Warburg Pincus agrees to take the eye-care company private. Investors, take note.
The Motley Fool July 22, 2004 Nathan Slaughter	VISX Eyes Future The vision-correction firm posts triple-digit earnings growth, capturing the attention of investors.
The Motley Fool May 15, 2006 S.J. Caplan	Bausch & Lomb Blinks Facing accounting and product woes, the eye-care company delays filing. Ratings agency Fitch has now lowered the company's credit ratings to just one notch above junk status. Investors, take note.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
Pharmaceutical Executive February 1, 2012 Ben Comer	Prizing the Eye : Brent Saunders, CEO Bausch + Lomb Bausch + Lomb CEO Brent Saunders refocuses on the customer.
Popular Mechanics March 2007 Alex Hutchinson	Forget Fisheye: A Photo Lens to Steer Robots A lens developed by South Korean researchers offers a wide-angle view without fisheye distortion, perfect for ceiling-mounted security cameras. Unlike images produced by fisheye lenses, straight lines appear straight.
The Motley Fool February 11, 2005 Stephen D. Simpson	For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant.
The Motley Fool March 29, 2007 Selena Maranjian	Beware Margin Borrowing High levels of margin may suggest an increase in reckless investing in the market, which might possibly lead to some kind of market meltdown.
The Motley Fool January 4, 2010 Brian Orelli	You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon.
The Motley Fool December 17, 2007 Anders Bylund	3 Stocks That Missed the Mark These companies overpromised and underdelivered: Cooper Companies... FreeSeas... CDC Corp...
The Motley Fool October 21, 2008 Brian Orelli	Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.
The Motley Fool January 31, 2007 Brian Lawler	No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now.
The Motley Fool October 12, 2006 Tim Hanson	5 Turnaround Stocks These stocks are down, but not out: Bausch & Lomb... Compucredit... Intersections... Syneron Medical... etc.